IP Library › Granted Patent US 11,117,895
Granted Patent B2
US 11,117,895 · App. 16/297,550 · Granted Sep 14, 2021

Process for producing crystals of a diazabicyclooctane derivative

Inventors: Takaya Ogawa (Kanagawa, JP); Takuya Yokoyama (Kanagawa, JP); Shusuke Furuyama (Kanagawa, JP); Masato Ichiki (Kanagawa, JP); Kenichi Fushihara (Kanagawa, JP)
Assignee: MEIJI SEIKA PHARMA CO., LTD.
C07D471/08A61K9/0019A61K9/19A61K31/439A61K47/02C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,117,895
App. No.
16/297,550
Granted
Sep 14, 2021
Kind
B2
Abstract

A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.

Claims (13)

1. A process for producing crystals of a compound represented by the following formula (I):

comprising crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, without previous purification of the compound with a column,

wherein a crystalline form I of the compound having characteristic peaks appearing at a lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in a powder X-ray diffraction pattern is produced.

2. A process for producing crystals of a compound represented by the following formula (I):

comprising crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, without previous purification of the compound with a column,

wherein the aqueous solution containing the compound and an inorganic salt is obtained by dissolving the compound and the inorganic salt together in water, or by dissolving either of the compound or the inorganic salt in water and then dissolving the other in the resultant solution, and

wherein a crystalline form I of the compound having characteristic peaks appearing at a lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in a powder X-ray diffraction pattern is produced.

3. A process for producing crystals of a compound represented by the following formula (I):

comprising crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, without previous purification of the compound with a column,

wherein the compound is crystallized by adding a poor solvent to the aqueous solution containing the compound and the inorganic salt, and

wherein a crystalline form I of the compound having characteristic peaks appearing at a lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in a powder X-ray diffraction pattern is produced.

4. The process according to claim 3 , wherein the poor solvent is an alcohol.

5. The process according to claim 1 , wherein the compound is crystallized by subjecting the aqueous solution containing the compound and the inorganic salt to lyophilization.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2019
From: OGAWA, TAKAYA; YOKOYAMA, TAKUYA; FURUYAMA, SHUSUKE; ICHIKI, MASATO; FUSHIHARA, KENICHI
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 048553/0208 →
Priority Claims (1)
JP 2014-246425 · Dec 5, 2014 · national
Continuity (2)
Division 15532281
Related Publication 20190202831A1 · Jul 4, 2019